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randomised controlled trial
Hillary Rono1,2* , Andrew Bastawrous1,4, David Macleod1, Emmanuel Wanjala2, Stephen Gichuhi3 and
Matthew Burton1
Abstract
Background: Globally, eye care provision is currently insufficient to meet the requirement for eye care
services. Lack of access and awareness are key barriers to specialist services; in addition, specialist services are over-
utilised by people with conditions that could be managed in the community or primary care. In combination,
these lead to a large unmet need for eye health provision.
We have developed a validated smartphone-based screening algorithm (Peek Community Screening App). The
application (App) is part of the Peek Community Eye Health system (Peek CEH) that enables Community
Volunteers (CV) to make referral decisions about patients with eye problems. It generates referrals, automated short
messages service (SMS) notifications to patients or guardians and has a program dashboard for visualising
service delivery.
We hypothesise that a greater proportion of people with eye problems will be identified using the Peek CEH
system and that there will be increased uptake of referrals, compared to those identified and referred using the current
community screening approaches.
Study design: A single masked, cluster randomised controlled trial design will be used. The unit of randomisation will
be the ‘community unit’, defined as a dispensary or health centre with its catchment population. The community units
will be allocated to receive either the intervention (Peek CEH system) or the current care (periodic health centre-based
outreach clinics with onward referral for further treatment). In both arms, a triage clinic will be held at the link health
facility four weeks from sensitisation, where attendance will be ascertained. During triage, participants will be assessed
and treated and, if necessary, referred onwards to Kitale Eye Unit.
Discussion:We aim to evaluate a M-health system (Peek CEH) geared towards reducing avoidable blindness through
early identification and improved adherence to referral for those with eye problems and reducing demand at secondary
care for conditions that can be managed effectively at primary care level.
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Background
Globally, it is estimated that 253 million people have visual
impairment (VI; visual acuity in the better eye < 6/18), 36
million of whom are blind (visual acuity in the better eye <
3/60) [1]. About 80% of the impairment is avoidable [2].
Approximately 90% of those who are living with VI are in
low- and middle-income countries [3]. Although the preva-
lence of moderate or severe vision impairment in adults
aged ≥ 50 years is higher in South and Southeast Asia,
North Africa, and the Middle East [4], sub-Saharan Africa
(SSA) has the greatest gap between need (blindness VI) and
available eye services [5]. In Kenya, the prevalence of blind-
ness is high; it is in the range of 0.6–2.0%, depending on
the region [6–10]. There are only 115 ophthalmologists for
a population of 49 million. Moreover, their distribution is
very uneven, in the range of 0–17 per 1 million population
across the various counties [11].
The causes of blindness vary according to regions and
countries [12–15]. Globally, the leading causes of VI are
uncorrected refractive error and cataract, while cataract
and glaucoma are the leading causes of blindness [2, 16].
Other causes of blindness include diabetes, macular de-
generation, and other posterior eye diseases [7, 10, 17].
The reasons for a high burden of VI include poverty and
a lack of access to eye services [18]. Patient factors such as
lack of awareness, fear of treatment outcomes, increasing
age, female gender, and presence of diabetes increase the
risk of blindness [10, 19]. Health system-related factors in-
clude low numbers of eye workers, variable productivity,
high indirect and direct costs, and the mal-distribution of
the work force, which currently favours major urban areas
[20–23]. In addition, there are ‘provider’ factors, such as
poor-quality services arising from a shortage of trained
staff and infrastructure [19, 24]. There is a large disparity
between the need for eye services and availability of eye
care workers [5].
To improve access to eye health services, especially in
rural areas, outreach programs designed to promote ac-
cess to eye services by communities in remote regions
have been used [22, 25]. They provide short-term access
to eye services for patients; however, the long-term goal is
to integrate eye services into primary healthcare (PHC) as
a continuum of health service provision [26, 27]. Redistri-
bution of tasks among health workforce teams, to improve
efficiency among available human resources, have also
been used with variable success [9, 28]. Effective task shift-
ing with clear referral criteria and management plans has
been successfully delivered through algorithms such as
the Integrated Management of Childhood Illness (IMCI)
at primary level [29, 30]. In eye care, decision trees and al-
gorithms have been developed, mostly outside Africa, and
focused on identifying the diagnosis and treatment at a
secondary level [31–33]. The World Health Organization
(WHO) recently developed similar algorithms and train-
ing manual for use at the PHC facilities in Africa [34]. To
our knowledge, there are no digital algorithms to identify
and refer people from communities.
Rationale
There is a clear need for improved access to eye health
services for populations in many regions of the world.
Availability of mobile phone technology and its usage in
healthcare, including eye care, is increasing rapidly [35, 36].
One such example is Peek acuity, which has developed ap-
plications (Apps) for measuring visual acuity [37]. One
study in Kenya showed that the Peek Visual Acuity App
was a repeatable, accurate and reliable measure of visual
acuity in adults [38]. This App was found to be acceptable
to patients, care givers and stakeholders [39]. Another study
among school-going children compared the performance of
teachers using the Peek Acuity App to assess children’s vi-
sion to a clinician assessing the same children using as
standard backlit EDTRS LogMAR visual acuity test chart
found a sensitivity of 77% (95% confidence interval [CI] =
64.8–86.5) and specificity of 91% (95% CI = 89.3–92.1)
[40]. We initially developed and validated the ‘Peek com-
munity screening App’ that allows referral decisions to be
made precisely and reliably across all ages for the trial.
Results from the validation of this App showed that com-
munity volunteers (CV) could accurately make referral
decisions (manuscript in preparation).
A recent systematic review showed that mobile health
(m-Health) interventions that support communication
between healthcare providers and patients through short
messaging service (SMS) appointment reminders are
beneficial [41]. Similarly, outreach service provision in
India incorporated the electronic transfer of health-re-
lated data from outreach clinics to base hospitals with
some success [42]. This provides an opportunity for a
combined outreach model, which incorporates triage
and referrals aided by mobile technology.
We recently conducted a cluster randomised con-
trolled trial in primary schools in Kenya using the Peek
School Eye Health system. The system uses the Peek
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Acuity App to detect VI in school children. For those
that then screen positive and who require further assess-
ment or follow-up, it generates automated text messages
to parents/guardians and contact teachers, as well as
real-time notifications to hospital services. We found
that teachers could reliably screen for VI. Uptake of
referrals to eye care providers was substantially higher in
the Peek intervention arm of this school trial [40]. This
trial provided evidence that m-Health solutions could be
used to improve access to eye health services.
In this new trial, the Peek Community Eye Health (Peek
CEH) system will be compared to the current standard
approach of periodic health centre-based outreach clinics.
The system uses the ‘Peek Community Screening App’,
which is a smartphone-guided algorithm for supporting
‘Peek Users’ to identify and refer people with visual
impairment and other eye problems in the community.
Peek Users are CVs who are trained specifically in how to
use Peek. They travel to multiple communities to perform
their duties. During community outreach, they work with
the local CVs to identify and refer patients needing oph-
thalmic attention. Although treatment will be provided at
no cost, it is assumed that: (1) all patients trust the health
system; (2) eye health workers have the capacity and able
to manage all conditions; and (3) relevant treatment
modalities will be available.
Objectives
The objective of this cluster randomised trial is to test
the hypothesis that the Peek CEH system can increase
access to eye services through: (1) increased identifica-
tion of people with impaired vision and eye problems in
the community; (2) increased uptake of a referral within
four weeks by patients with identified an eye problem;
and (3) more appropriate utilisation of primary and sec-
ondary care services at each health system level.
Methodology
This protocol is structured in accordance with the Stand-
ard Protocol Items: Recommendations for Intervention
Trials (SPIRIT) 2013 Checklist [43] (see Additional file 1).
Trial design and overview
This trial is a single-masked, parallel-group, cluster rando-
mised controlled trial. Thirty-six community units with
their health facilities (dispensary or health centres) will be
randomly selected to receive either the intervention (com-
munity screening using the Peek screening system) or the
current standard of care (periodic health centre-based
outreach clinics). The health workers involved in the study
will be trained to ensure standardised screening. Partici-
pants who provide consent will be enrolled to the arm to
which their cluster is randomised.
In the Peek arm, all households in the cluster will be vis-
ited in turn. Consenting individuals will have their visual
acuity tested using the Peek visual acuity screening appli-
cation on a smartphone. All participants with reduced
visual acuity or reporting another eye problem will be re-
ferred to the linked PHC for assessment and management.
Those requiring treatment not available from the PHC
facility will be referred onwards to Kitale Eye Unit (KEU).
In the control arm, communities will be notified about the
periodic eye health outreach clinic that will be held in the
local health centre. People attending this service will be
assessed and, if necessary, referred onwards to KEU.
The participants will be followed up for eight weeks
after referral from the community. The primary outcome
will be the number of people per 10,000 population
(rate) attending triage at a local health facility (PHC)
with any confirmed eye conditions (true-positive cases
determined at triage by hospital outreach team) follow-
ing a referral or by self-referral within four weeks from
the time of sensitisation. The secondary outcome will be
the proportion of people referred from the PHC triage
attending their referrals at KEU within four weeks of
being referred. A participant (standard or Peek) who
attends the hospital appointment within four weeks will
be considered an ‘attender’ while anyone who is referred
but does not attend within the same time is a ‘non-
attender’.
Participant timeline and study flow chart
The study flow chart and participant timeline are pre-
sented in Fig. 1 and Table 1, respectively.
Participants, interventions and outcomes
Study setting
The trial will be conducted in community units that are
served by government-run dispensaries and health cen-
tres in Trans Nzoia County in northern Kenya. Trans
Nzoia County has a population of 818,757 people (2009
census) of which 407,172 (49.7%) were male [44]. It is
organised into five sub-counties. There were 173,719
households, with an average of five people per house-
hold. The large majority have no Internet access (669,
347, 81.8%) [45]. There are 61 government facilities (six
hospitals, 12 health centres, 43 dispensaries) and 76
facilities owned privately or by faith-based organisations
[46]. Eye services are offered at KEU and through out-
reach services, provided by eye care staff from KEU to
other health facilities. Screening and treatment of eye
conditions (triage) is offered during outreach. The trial
will be coordinated from Kitale Hospital by a team
consisting of a programme manager, administrator, oph-
thalmic nurses, field workers and an ophthalmologist.
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Fig. 1 Trial design outline: randomisation, interventions and flow of participants
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Cluster definition
The unit of randomisation for this trial will be Community
Units (CU). These are defined as a dispensary or health
centre together with the community they serve (Fig. 2).
A typical CU comprises a population of 5000–10,000
people. It has a dispensary or health centre, staffed by
one or two Community Health Extension Workers
(CHEWs). Associated with each CU, there are usually
20–50 CVs [47]. The CHEWs based at the health centre
or dispensary train, support and supervise the CVs. To
date, 85 CUs have been established and personnel
trained in this county [46]. CUs were chosen because it
represents the future shape of healthcare in Kenya; they
are distributed throughout the county and have a good
referral network that provides linkages between com-
munity and health system. The CUs with untrained
Table 1 Project timeline
Study period
Enrolment Allocation Post allocation Close-out
Week – 2 − 1 0 1 2 3 4 5 6 7 8 9
Preparation
Training of field workers X X
Approvals: Trans Nzoia health
department and head of
health facilities
X
Community enumeration and
obtaining consent
X X
Allocation of community units X
Interventions
Community sensitisation X
Peek package (community
screening, automatic reminder
short text messaging)
X X X
Standard care X
Triage treatment camp X
Peek referral reminders to attend
Kitale Eye Unit (automatic reminder
short text messaging)
X X X X X
Assessment
Attendance (uptake) of referrals X X X X X
Fig. 2 Community units, levels of healthcare and referral pathway (prepared by Andrew Bastawrous)
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personnel provide a buffer zone that will minimise
contamination.
Cluster eligibility criteria
A list of all health facilities with their geo-coordinates as
well as corresponding CUs and catchment population will
be obtained from the Trans Nzoia County Department of
Health. The location of each hospital will be determined
using Google Maps. Health facilities without CUs, those
with existing screening programs and the communities
directly served by KEU will be excluded. We will also ex-
clude all the non-government health facility-associated
CUs. From the remaining 66 CUs, a total of 36 CUs will
be randomly selected for the study. A restricted cluster
random sampling technique (described below) will be
applied to allocate the selected CUs to the Peek interven-
tion (18 CUs) or the standard care group (18 CUs). The
restriction will be based on the distance and location of
the CU’s heath facility relative to KEU.
Participant eligibility criteria
All people who consent to participate and present in
the community unit area during the study period will
be included. People who are unwilling to give consent
or who have had an eye condition treated at hospital
within two weeks before the beginning of the study
will be excluded.
Interventions
A comparison of the two arms is shown in Table 2 and
Fig. 1. Before the beginning of the trial, households in
each of the clusters in both arms will be visited by the
field team to explain the study, obtain consent (see Add-
itional file 2) and enumerate the residents. Parents/
guardians will provide consent for children. At the be-
ginning of the trial, in both arms, there will be posters
and verbal notices (churches and schools) advertising
the forthcoming outreach clinic for eye checks, encour-
aging people with eye problems to self-report to the
clinic on a specific date when the team will visit.
Peek CEH intervention arm In each cluster, a small
mobile team of a ‘Peek User’ (CVs trained specifically on
how to use the Peek Community Screening App and
who travel to multiple communities to perform their du-
ties) and local CV will visit each household. The CV, a
person from that same community, will guide the Peek
User around the village. After reconfirming consent,
people who are resident in the household at the time of
the visit will have a vision assessment. The visual acuity
of each eye will be measured separately using the Peek
Acuity App [38]. This smartphone application presents a
series of E-optotypes in one of four orientations, selected
at random. The test algorithm prompts the following
screening questions to the parents or guardian with a
child (‘Does the child have any problem with their eyes
Table 2 Comparison of the interventions in the two arms of the trial
Intervention arm Control arm
Consent and enumeration Yes Yes
Community sensitisation Posters and announcement in
churches and schools
Posters and announcement
in churches and schools
Community screening Vision assessed at household level
using Peek E- acuity by field worker
No vision assessment at
household level
Screening decision using Peek
Screening App
No screening
Personalised text and weekly reminder
messages for participants/carers in the
relevant local language to attend
appointments
No text message
Referral from community to PHC (triage centre) Self-referring participants and referrals by
CV using Peek system?
Self-referring participants
Automatic referral through Peek system No referrals
Provision of triage Trained team composed of ophthalmic
clinical officer, ophthalmic nurses and two
field workers
Trained team composed of
ophthalmic clinical officer,
ophthalmic nurses and two
field workers
Referral from triage centre to secondary care Paper referral Paper referral
Automatic referral through Peek system
and weekly reminder SMS
Assessment of primary outcome Same for both arms (trained field worker) Same for both arms
(trained field worker)
Assessment of referrals Ophthalmic clinical officer Ophthalmic clinical officer
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today?’) or directly to participant themselves (‘Do you
have any discomfort or pain in your eyes today?’ and ‘Do
you have a problem with your sight when seeing far or
near objects?’). If the participant is aged ≥ 6 years, the
App prompts for distant visuals acuity assessment using
Peek Acuity App and assessment of near visual acuity
for all people aged ≥ 40 years. Near vision will be
assessed at 40 cm using the RADNER reading chart [48].
They will be referred to the PHC for subsequent assess-
ment by the visiting time if: the visual acuity is < 6/12 in
either eye; there is any self-reported eye pain or discom-
fort; there is difficulty seeing distant or near objects; or
they are not able see N8 on near vision assessment.
Household members absent during the first visit will be
asked to join the examination team at the next house-
hold or next day.
Those who have reduced visual acuity on screening or
report an eye problem will be referred to a health post for
triage on a specific date when the KEU team visit. The sys-
tem will generate several SMS text messages: (1) to the
patient and family associate asking them to present to the
health facility on a specific day (set to be within four
weeks); (2) the CV will receive an SMS list of patients
from their community that have been referred; and (3) the
CHEW responsible for that CU will similarly receive the
same list of referred patients. A weekly reminder SMS will
be sent to the patient for them to attend their referral
appointment with the last reminder being one day before
the appointment.
On the pre-advertised date, a team from KEU will be
based at the CU’s dispensary. The participants referred
from the household screening because of reduced vision or
a specific eye problem will be reminded to attend. They will
assess the presenting patients using the current standard
procedure (Snellen chart visual acuity, magnifying loop, re-
fraction and direct ophthalmoscopy when indicated). They
will provide simple treatments or refer patients to KEU for
further assessment as indicated. A pre-numbered paper re-
ferral letter will be given to the patient to present at KEU.
The referral slip has their study number, name and triage
centre, and telephone number, and indicates that assess-
ment and treatment will be provided at no cost. It is
expected that they will report to KEU within four weeks
from being referred.
Immediately after referral from the PHC, an SMS will
be sent to the patient and the family associate asking them
to present to KEU. A weekly reminder SMS will be sent
for those who have not attended their referral to KEU. An
SMS with a list of patients who have not attended their re-
ferral will be sent to the CHEW responsible for the PHC.
Standard of care (control) arm In the control arm,
there will be no active Peek screening in the community;
however, potential participants with eye problems at the
community will be notified through community sensi-
tisation (posters and local announcements) that if they
have an eye problem to present themselves to the health
facility for the triage clinic on a specified date. On that
advertised date, the team from KEU will conduct an out-
reach clinic within the CU, which will be identical to the
ones in the Peek arm described above. If an individual
needs to be referred to KEU, they will be given an identi-
cal referral letter to the ones used in the Peek arm. Each
letter will have a unique code number to link the patient
referral record to their KEU attendance.
Outcomes
Primary outcome The primary outcome is the number
of people per 10,000 population (rate) attending triage at a
local health facility (PHC) with any confirmed eye condi-
tions (true positives) following a CV referral or by self-re-
ferral, within four weeks from the time of sensitisation.
The rate will be based on baseline enumeration census for
each CU. The true positives will be determined at triage
by the hospital outreach team.
Secondary outcomes The secondary otucomes are: (1)
the number of people per 10,000 (rate) attending the tri-
age post without any eye condition (false positives) as de-
termined by the eye team; (2) the number of people per
10,000 population (rate) attending KEU within four weeks
after being referred from PHC; (3) the proportion of par-
ticipants referred from the PHC who attend the referral at
KEU within four weeks of being referred from a PHC; and
(4) the time taken by a participant referred from PHC to
attend KEU.
Sample size
The sample size of 36 clusters was determined using the
Hayes formula for rates in unmatched cluster rando-
mised trials [49]. In Trans Nzoia County, a typical health
facility has a catchment population of 5000 people [46].
During previous community outreaches to these health
facilities, about 50–100 new patients attended. This
translates to an average rate of 15 per 1000 population
[50]. Assuming an intraclass correlation coefficient of
0.001, desired power of 90% and significance level of 5%,
a sample of 36 CUs (18 in each arm) would be sufficient
to detect a difference of 0.5%, from 1.5% in the control
arm to 2.0% in the intervention arm (a 33% relative
change) in overall attendance rates.
Assignment of interventions
Allocation There are 66 potentially eligible CUs in the
county (see above). We will select 36 CUs for inclusion
in the trial. In order to ensure balance between the arms,
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restricted randomisation will be used. A list of the 66
CUs with their sub-county, distance from Kitale and dir-
ection from Kitale (categorised into four quadrants,
North, South, East and West) will be compiled and used
during randomisation. A statistician, who will not par-
ticipate in recruitment, will generate a random allocation
sequence. Randomisation will consider the direction,
cluster size and distance from the hospital. The follow-
ing restrictions will be used in the randomisation:
 each arm must include at least two CUs from each
sub-county;
 each arm must include at least two CUs from each
direction of North, South, East and West;
 the ratio between number of CUs in each arm from
each direction must be in the range of 0.67–1.5;
 the difference in mean health centre distance from
Kitale in each of the arms should not be > 4 km; and
 there should not be more than one CU per link
health facility.
A list of 10,000 valid permutations will be generated
and checked that there are no clear deviations in ran-
domness (e.g. pairs of health centres that occur within
the same arm considerably more/less often than would
be expected by chance). One of these 10,000 permuta-
tions will be computer-selected at random. A list of CUs
allocated to the control group, intervention group and
those not involved will be prepared.
In health facilities where there are larger catchment
populations and served by more than one CU, one of
the CUs will be randomly selected along with its popula-
tion unit, so that the size of the clusters studied is
around 5000.
Masking
It will not be possible to mask the participants or the health
workers from the intervention to which they are allocated;
however, the study statistician, hospital registration clerk
and clinician assessing outcomes will be masked. The data
clerk will be masked to the intervention arm because all
the patients will present with paper referral. The clinician
assessing secondary outcomes will not participate in patient
recruitment or assessing attendance and all patients will be
given similar assessment questionnaires. The statistician
will not participate in patient recruitment.
Data collection, management and analysis
Data collection In both arms, we will use electronic
data capture and management using dedicated Peek soft-
ware with built-in consistency checks. In both arms, this
will include the enumeration data, the triage data in the
health centre/dispensary and the outcome data collected
in the KEU. In addition, the household screening data
will also be captured electronically for the Peek arm dur-
ing the study period and in the control arm following
the study when the team will screen all the control clus-
ters. Field workers will be provided with tablets for data
entry. Information will be backed up regularly.
During triage assessment at the health centre/dispens-
ary, trained field workers will verify that the participant
comes from the catchment population. From each eligible
participant, date of attendance, name, age, gender and
own or parents’ mobile phone number, whether referred
using the Peek system or self-referral, the diagnosis and
treatment plan (treated or referred) will be obtained. At
KEU, all referred patient will be marked as attended upon
presentation and record the date of visit, diagnosis and
outcome of the visit.
Data management
Data will be entered directly onto smartphones by
trained field workers and uploaded to a secure server
once connected to the Internet before being exported
into Stata for analysis. The database will be encrypted
and password-protected. At the end of the study, the
data will be archived at LSHTM.
Data analyses The trial will be reported using the 2010
CONSORT guidelines, with the cluster RCT extension
[51]. Analysis will be by intention to treat. Socio-demo-
graphic characteristics of participants at baseline will be
tabulated by arm: age; sex; residence; and distance from
hospitals (categorised distances). The distributions of
these variables by intervention arm will be compared to
assess whether there is imbalance at baseline in these
potential confounding factors.
Analysis of the primary outcome
The proportion of individuals attending triage within
each cluster will be calculated, by dividing the number
attending triage and having a confirmed eye condition
by the cluster population, which will be determined by
the baseline enumeration census in both arms (true-
positive attendance rate). A t-test will be performed on
these cluster-level rates providing an estimate of the rate
difference (with a 95% CI) between the two arms and a
P value in order to assess the strength of evidence
against the null hypothesis that the rate is equal in the
two arms [52]. The two study arms should be balanced
in terms of confounders due to the restricted randomisa-
tion process so the primary analysis will be unadjusted.
Analysis of secondary outcomes
The proportion attending triage but having no eye con-
dition (false-positive attendance rate) will be estimated
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in a similar manner to the above in both arms, with a
rate difference estimated, along with its 95% CI.
In order to estimate the effect of the intervention on the
attendance rate of true positives at KEU the approach will
be identical to the cluster-level analysis of the primary
outcome. The numerator of each cluster is the number of
individuals attending KEU following a referral from triage
and the denominator is the cluster population. Again, a t-
test will be used to assess the evidence as to whether the
rate differs between arms and the analysis will again be
unadjusted.
The difference in the proportion of patients referred
from the PHC to the KEU who attend their referral within
four weeks, by arm, will be tested using a random effects
logistic regression, with attendance at KEU as the out-
come, trial arm as the primary exposure and cluster as a
random effect to account for within cluster correlation.
Due to the fact that the characteristics of the patients re-
ferred in each arm may be different (due to the potential
upstream impact of the intervention), this analysis will be
adjusted for sex, age group and distance from KEU.
The impact of the intervention on time-to-attendance
will be investigated, using Kaplan–Meier plots for each
arm to compare attendance of referral. The hazard ratio
will be estimated using Cox regression, again adjusted
for sex and age group, to assess whether patients re-
ferred in the intervention arm attended their referrals
sooner than those in the control arm..
We will assess possible effect modification of sex, age
and distance from KEU. In the cluster-level analyses, the
approach recommended by Cheung et al. [53], will be
used for age and sex, where the rate in each group within
each cluster will be estimated, then the difference in this
rates in each group found, before finally performing a t-
test on these differences by arm. In order to identify if the
distance from KEU is an effect modifier, since it is a clus-
ter-level covariate, this can be done by performing a linear
regression on the cluster level rates and include distance
and trial arm as exposures with an interaction term be-
tween them. For the individual-level analyses, an inter-
action term will be included with trial arm for each of the
potential effect modifiers (age, sex, distance from KEU).
Monitoring
Data monitoring
The study presents minimal risk and we do not antici-
pate significant adverse events. Therefore, a data and
safety monitoring committee was not considered neces-
sary; however, an audit will be done by the London
School of Hygiene and Tropical Medicine (LSHTM),
the Trial Sponsor, if it is deemed necessary. No interim
analysis is planned due to the relatively short duration
of the study.
Harm
The tests being done are in routine clinical use in Kenya
and internationally. There are no anticipated harms from
this non-invasive assessment process in either arm. As-
sessment in the community will take 5min per person.
Experienced certified ophthalmic clinical officers will
provide treatment for all participants with eye problems,
under the supervision of an ophthalmologist.
Protocol amendments
There have been no protocol amendments since the
initial application. Amendments to the protocol are not
currently anticipated; however, if they are required they
will be submitted to the two committees mentioned
above.
Consent
Trained field workers will obtain written informed con-
sent from all participants. Where an individual is unable
to read, the information will be read to them and their
consent documented by thumbprint, in the presence of
an independent witness. Consent for children will be
obtained from parents or guardians accompanying them.
A copy of the information sheet will be given to each
participant. Verbal assent will also be obtained from
children before being examined.
Confidentiality
Data will be anonymised before analysis and long-term
storage by the removal of personal identifying informa-
tion. The Peek database will be encrypted and password-
protected with access only granted to staff involved in the
study. Data with identifiable information will be secured
within a locked project office at KEU, with limited access
to only authorised staff.
Access to data
Investigators at LSTHM and Kitale Hospital will have
access to the final trial dataset. An agreement exists on
data sharing and intellectual property. All the data will
be archived at LSHTM after the study is completed.
Post-trial care
Given that the trial is being conducted by KEU, it is inte-
grated into existing health systems through which the
patients will be managed. The control arm clusters will
have the same screening service as the intervention arm
after the end of the trial.
Dissemination
Summary of the findings will be provided for local stake-
holders, Ministry of Health and participating institutions.
Publications will be submitted to peer-reviewed journals
(open access) and presentations made at regional and
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international conferences and meetings in Kenya and the
United Kingdon.
Discussion
This trial is designed to evaluate whether the Peek
Screening system in the community increases access to
eye services at PHC within four weeks for patients with
eye problems, as well as to assess whether the same sys-
tem increases uptake of referrals of people identified
with eye problems from PHC to secondary care within
four weeks.
One identified limitation of the study would be the
number of people who will be screened and referred but
have no eye problems (false positives) and may potentially
overload the health system. Through the trial, we shall
analyse the potential limitations with a view of under-
standing and providing potential solutions in the future.
The WHO and International Agency for Prevention of
Blindeness (IAPB) have set a target of eliminating avoidable
blindness by 2020 through early identification and treate-
ment. This study aims to evaluate a system to reduce the
prevalence of people with VI through early identification
and referral from the community for those with ophthalmic
ailments. The system will potentially increase access and
uptake of eye services through screening and referral by
CVs, for those with eye problems. Through the system, we
shall be able to track the process of screening and referral
of patients with a view of identifying gaps in the health sys-
tem and advise policy makers on potential solutions. The
results will therefore be relevant and contribute towards
realising this goal.
Trial status
At the time of submission, recruitment was ongoing. Re-
cruitment started on 26 November 2018 and is expected
to be completed on 09 April 2019. It was registered by
Pan African Trials Registry on 8 June 2018.
Additional files
Additional file 1: Standard Protocol Items: Recommendations for
Intervention Trials (SPIRIT) 2013 Checklist. (DOC 122 kb)
Additional file 2: Informed consent materials. (DOCX 112 kb)
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